Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses
- 1 December 2010
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (23), 5722-5733
- https://doi.org/10.1158/1078-0432.ccr-10-1693
Abstract
Purpose: Preclinical murine model systems used for the assessment of therapeutics have not been predictive of human clinical responses, primarily because their clonotypic nature does not recapitulate the heterogeneous biology and immunosuppressive mechanisms of humans. Relevant model systems with mice that are immunologically competent are needed to evaluate the efficacy of therapeutic agents, especially immunotherapeutics. Experimental Design: Using the RCAS/Ntv-a system, mice were engineered to coexpress platelet-derived growth factor B (PDGF-B) receptor + B-cell lymphoma 2 (Bcl-2) under the control of the glioneuronal specific Nestin promoter. The degree and type of tumor-mediated immunosuppression were determined in these endogenously arising gliomas on the basis of the presence of macrophages and regulatory T cells. The immunotherapeutic agent WP1066 was tested in vivo to assess therapeutic efficacy and immunomodulation. Results: Ntv-a mice were injected with RCAS vectors to express PDGF-B + Bcl-2, resulting in both low- and high-grade gliomas. Consistent with observations in human high-grade gliomas, mice with high-grade gliomas also developed a marked intratumoral influx of macrophages that was influenced by tumor signal transducer and activator of transduction 3 (STAT3) expression. The presence of intratumoral F4/80 macrophages was a negative prognosticator for long-term survival. In mice coexpressing PDGF-B + Bcl-2that were treated with WP1066, there was 55.5% increase in median survival time (P < 0.01), with an associated inhibition of intratumoral STAT3 and macrophages. Conclusions: Although randomization is necessary for including mice in a therapeutic trial, these murine model systems are more suitable for testing therapeutics, especially immunotherapeutics, in the context of translational studies. Clin Cancer Res; 16(23); 5722–33. ©2010 AACR.Keywords
This publication has 63 references indexed in Scilit:
- Glioma cancer stem cells induce immunosuppressive macrophages/microgliaNeuro-Oncology, 2010
- STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinomaBritish Journal of Cancer, 2010
- IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomasProceedings of the National Academy of Sciences of the United States of America, 2009
- Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor MicroenvironmentCancer Cell, 2009
- A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cellsCancer Immunology, Immunotherapy, 2008
- Insulin-like growth factor binding protein 2 promotes glioma development and progressionProceedings of the National Academy of Sciences of the United States of America, 2007
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004
- The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapiesThe Journal of Pathology, 2002
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958